Undisclosed tau degrader / SEED Therapeutics - LARVOL DELTA

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones (GlobeNewswire) - "Expected 2025 Milestones - Plinabulin: 1H 2025: Updated data from Phase 2 of Study 303 in metastatic NSCLC progressed on PD-1/PD-L1 inhibitors. 2H 2025: Preliminary data from Phase 2 of Study 302 in 1L ES-SCLC. SEED: Mid-2025: Expected IND filing of RBM39 degrader. 2H 2025: RBM39 degrader expected to begin patient enrollment. 2H 2025: Tau degrader expected to achieve in vivo efficacy."

IND • New trial • P2 data • Non Small Cell Lung Cancer • Small Cell Lung Cancer

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics (GlobeNewswire) - "The SEED TPD platform referred to as RITE3, has translated the scientific breakthrough...Differentiated from other molecular glue companies, which are mainly 'E3 centric', SEED’s RITE3 platform is 'target centric' and uses novel E3 ligases for protein targets. With detectable weak basal interaction between selected E3 and protein target, the binder hit rates from its high throughput screening is higher...SEED expects to file an IND in early 2025 for its IND Candidate oral RBM39 degrader, for the treatment of rationally selected cancer indications; SEED R&D has a focus on the development of orally delivered molecular glues for CNS indications, with a lead internal program against Tau...Eli Lilly is a current investor and R&D collaborator with upfront and milestone payments up to $780 million....'I'm delighted to announce SEED's substantial progress...Tau degraders for neurodegeneration advancing towards lead molecule status towards the end of 2024.'"

IND • Licensing / partnership • New molecule • CNS Disorders • Oncology • Solid Tumor